Skip to main content

Molybdenum Cofactor Deficiency

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Origin
OriginRUSTON, LA
1 program
A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase DeficienciesN/A1 trial
Active Trials
NCT01735188Completed65Est. Jun 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OriginA Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies

Clinical Trials (1)

Total enrollment: 65 patients across 1 trials

NCT01735188OriginA Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies

A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies

Start: Aug 2013Est. completion: Jun 201665 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.